MARKET WIRECNBC • 2h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why BJDX Stock dropped -5.08% Today — RQD Quant Desk Flash
$0.54 -5.08% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.53
Bluejay Diagnostics Inc. (BJDX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $2.4M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.53 (-1.10%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-5.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BJDX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (45/100 Composite)
🔍 WHY BJDX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$0.82-8.5% Next Q
53
Q2 (-2Q)Grade C-$0.75-22.7% Next Q
50
Q3 (-1Q)Grade D$0.58-6.9% Next Q
48
CurrentGrade D$0.54-6.3% Hist 90D α
45
Trajectory: C- (53) → D (45)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BJDX Turnaround Squeeze
While BJDX currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.82) and Max Pain ($0.57) forces dealer call-delta covering toward $8.34.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BJDX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BJDX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BJDX Stock dropped -5.08% Today — RQD Quant Desk Flash
Bluejay Diagnostics Inc. (BJDX) dropped -5.08% to $0.54, trading at 2% of its 52-week range ($0.46 – $7.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.46 – $7.94) with RSI-14 at 29.6 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.54 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BJDX Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BJDX)
- ✓Walkthrough of BJDX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BJDX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -70.17%▲ RESISTANCE BREAKOUT
2026-10-30O $0.53H $0.60L $0.46C $0.54VOL 280.9K
RES: $0.47SUP: $-0.26SMA50: $0.82SMA200: $1.85
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BJDX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BJDX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BJDX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BJDX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BJDX)
Health Care Rank #493 of 1016
⚔️ IVF vs BJDX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BJDX vs. IVF, NXGL, ICCM, CODX)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Bluejay Diagnostics Inc. (BJDX) ranks #493 by composite RQD confidence (45/100, grade D) and #990 by equity capitalization ($2.4M). Within this direct 5-issuer industry benchmark cohort, BJDX leads on earnings valuation at N/A trailing P/E, while BJDX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ICCM currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with BJDX at 45/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BJDX
ACTIVE
Bluejay Diagnostics Inc. | D | 45/100 | — | — | -35.0% | -5.08% | $2.4M | Benchmark Subject |
| IVF INVO Fertility Inc. | D- | 43/100 | — | 96.0% | -35.0% | -3.60% | $2.5M | /ivf-vs-bjdx → |
| NXGL NexGel Inc | E | 32/100 | — | 39.5% | -35.0% | -3.72% | $1.9M | /nxgl-vs-bjdx → |
| ICCM IceCure Medical Ltd. | D | 46/100 | — | 36.3% | -35.0% | -2.13% | $3.3M | /iccm-vs-bjdx → |
| CODX Co-Diagnostics Inc. | D- | 37/100 | — | 64.3% | -35.0% | -10.49% | $3.5M | /codx-vs-bjdx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001704287In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bluejay Diagnostics Inc. (BJDX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$6.8M, operating cash flow of -$6.1M, and free cash flow of -$6.2M (+23.4% YoY). On the balance sheet, BJDX closed FY2025 with $7.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$6.8M | -$6.1M | -$6.2M | $7.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$7.7M | -$7.8M | -$8.1M | $6.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$10.0M | -$8.3M | -$8.3M | — | — |
3. BJDX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BJDX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Bluejay Diagnostics Inc. (NASDAQ: BJDX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $0.54 (-5.08% 1D, market cap $2.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BJDX ranks #493 in composite RQD confidence.
How does BJDX compare to IVF and NXGL in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), BJDX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IVF (INVO Fertility Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $2.5M) and NXGL (NexGel Inc) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $1.9M). Among the 5-stock peer group, BJDX leads on earnings multiple (N/A) while BJDX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BJDX?
Per BJDX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001704287), Bluejay Diagnostics Inc. generated $0 in revenue, -$6.8M in net income, and -$6.2M in free cash flow against $7.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BJDX trading relative to its 50-day, 200-day, and 52-week technical levels?
BJDX last traded at $0.54 (-5.08% on volume of 98,288 shares), positioning the stock -34.15% below its 50-day simple moving average ($0.82) and -70.81% below its 200-day simple moving average ($1.85). Across its 52-week range of $0.46 to $7.94, BJDX sits at the 1.1% percentile with a 14-day RSI of 29.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.61).
BJDX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BJDX stock moving today?
Why BJDX Stock dropped -5.08% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.